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Purpose or Objective: to analyze possible clinical value of 
lymph flow visualization as the guide for irradiation of IMLN. 
 
Material and Methods: On the first stage of the study we 
combined data of 8 published studies that analyzed lymph 
flow from primary BC (4541 patients) after intra- peritumoral 
injection of nanosized 99mTc-colloids. Using this data we 
determined probability of lymph flow from BC of 
internal/central or lateral localization to IMLN. In 7 studies 
(4359 women) axillary staging was accompanied by biopsy of 
sentinel lymph nodes localized in internal mammary region. 
This data made it possible to estimate probability of IMLN 
metastatic invasion in relation with the status of axillary LN. 
At the final stage of the study we calculated probability of 
IMLN invasion by BC in 4 randomized and 2 observation 
studies that analyzed effect of IMLN irradiation on overall 
survival. Additionally, we tried to calculated possible 
additional gain in survival if patients from this 6 (4+2) trials 
would be treated according to lymph flow guided irradiation 
of IMLN. 
 
Results: According to results of 8 published studies lymph-
flow from lateral BC to IMLN was detected in 16% (727/4541), 
from internal/central lesions – in 35% (1589/4541).Evaluation 
of 7 studies (4359 women) showed that in patients with 
noninvolved axillary LN metastases in IMLN were revealed in 
7.8%, in patients with positive axillary nodes - in 38.1% cases. 
In all 6 studies that evaluated clinical value of IMLN 
irradiation, calculated probabilities of IMLN metastatic 
invasion in “high risk patients” didn’t exceed 10%. If IMLN 
irradiation would be performed only in patients with lymph 
flow to IMLN about 72.1%-76.8% of “high risk patients” would 
escape RT to IM region. In remained 23.2%-28.9% patients 
with visualized internal mammary sentinel lymph nodes their 
irradiation would improve overall survival from 1.6%-3.3% to 
6.9%-14.2%. 
 
Conclusion: visualization of lymph flow from breast cancer 
after intratumoral injection of 99mTc-nanocolloids make 
decision about irradiation of IMLN more precise and efficient. 
Irradiation of visualized IMLN can significantly (6.9%-14.2%) 
improved overall survival in this group of patients with BC. 
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Purpose or Objective: To assess the feasibility of 
Simultaneous Integrated Boost in Intensity Modulated 
Radiotherapy (SIB-IMRT) for breast cancer (BC) in the attempt 
to reduce the radiation treatment time. Results in terms of 
late toxicity and local control were compared with a control 
group (CG) of patients treated with 3-dimensional (3-D) 
conformal radiotherapy plus sequential boost. 
 
Material and Methods: MARA-2 was conceived as a single arm 
phase I-II trial. Patients with moderate-high risk BC were 
enrolled and treated with forward-planned IMRT technique. 
Whole breast and tumor bed received a total dose of 50 Gy 
and 60 Gy (10 Gy concomitant boost) in 25 daily fractions, 
respectively. In CG group, prescribed dose to the breast was 
50.4 Gy in 28 fractions with a sequential 10 Gy boost to the 
tumor bed in 4 fractions. Late skin and subcutaneous toxicity 
were evaluated using EORTC/RTOG scoring scale. 
 
Results: Four hundred and fifty one patients were included in 
our study (MARA-2: 321; CG: 130). Median follow up was 52 
months (range: 3-115). G1 and G2 late skin toxicities were 
acceptable without significant differences between the two 
groups. No G≥3 late skin toxicity was observed in MARA-2. At 
univariate analysis, late G1 and G2 subcutaneous toxicities 
were significantly higher in MARA-2 (p<0.001). 5-year G1 
subcutaneous late toxicity free-survival (LTFS) were 73.4% 
and 38.5% in CG and MARA-2, respectively; moreover, 5-year 
G2 subcutaneous LTFS were 96.5% and 80.0% in CG and MARA-
2, respectively. 5-year G3 subcutaneous LTFS was 0.9% in 
MARA-2 and 0% in CG, respectively. No differences were 
found in term of loco-regional control (LC) with a 5-LC of 
96.7% and 97.6% in CG and MARA-2, respectively (p=0.676). 
 
Conclusion: The use of SIB-IMRT technique in postoperative 
radiotherapy of BC allowed to reduce overall treatment time 
without significantly increasing the incidence of G>2 late 
effects. 
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Purpose or Objective: To evaluate the feasibility and 
toxicity profile in elderly women, with a diagnosis of early 
stage breast cancer, underwent to adjuvant hypofractionated 
Volumetric Modulated Arc Therapy (VMAT) and simultaneous 
integrated boost (SIB) after conserving surgery (CS).  
 
Material and Methods: Between September 2013 to March 
2015, 50 consecutive women with a diagnosis of early stage 
of breast cancer were treated with SIB-VMAT after CS in our 
Institution. Inclusion criteria were: age ≥ 65 years, pT1 -2 
disease, pN 0-1, no neoadjuvant chemotherapy, no-
metastatic disease. A dose prescription of 40.5 Gy in 15 
fractions was prescribed to the whole breast (PTVbreast) and 
an additional radiation dose of 48.5 Gy in 15 fractions to the 
tumour bed was prescribed (PTVboost). Hypofractionated 
treatment was purposed in patients with negative margins 
after surgery (> 1 mm). All patients were followed with 
periodic clinical evaluation. Acute toxicity were scored using 
EORTC/RTOG radiation morbidity score system. Both patient 
and physician recorded cosmetic outcome evaluation with a 
subjective judgment scale at the time of scheduled follow-
up. 
 
Results: Median follow-up was 20 months. At the time of the 
analysis, overall survival and local control rates were 100%. 
All patients completed the SIB-VMAT without interruptions. 
Acute skin toxicity was recorded as follow: grade 0 in 22 
patients (44%), grade 1 in 24 cases (48%), grade 2 in 4 
patients (8%). Regarding late adverse events, skin toxicity 
was registered as follow: grade 0 in 40 patients (80%), grade 
1 in 10 cases (20%). No toxicity ≥ grade 2 was registered. In 
